Analysts Issued MiMedx Group Inc (MDXG) Target Price at $12.00

Analysts Issued MiMedx Group Inc (MDXG) Target Price at $12.00

Shares of MiMedx Group Inc (NASDAQ:MDXG) have received an average recommendation of “Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $12.00.

MDXG has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of MiMedx Group in a research note on Thursday, February 23rd. Zacks Investment Research raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Tuesday, February 21st. TheStreet raised shares of MiMedx Group from a “c+” rating to a “b” rating in a research note on Thursday, March 16th. Piper Jaffray Companies initiated coverage on shares of MiMedx Group in a research note on Friday, March 3rd. They issued an “overweight” rating and a $10.00 price objective for the company. Finally, First Analysis cut shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 price objective for the company. in a research note on Tuesday, May 23rd.

MiMedx Group (NASDAQ MDXG) traded up 0.96% on Friday, hitting $13.68. 1,521,542 shares of the stock were exchanged. The company has a 50-day moving average of $13.08 and a 200 day moving average of $9.87. MiMedx Group has a 12 month low of $6.94 and a 12 month high of $15.40. The firm has a market cap of $1.44 billion, a P/E ratio of 97.71 and a beta of 0.97.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Friday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a net margin of 8.75% and a return on equity of 18.18%. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $72.60 million. During the same period last year, the firm earned $0.04 earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. Equities research analysts expect that MiMedx Group will post $0.30 earnings per share for the current fiscal year.

In other news, insider William Charles Taylor sold 26,000 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $11.40, for a total value of $296,400.00. Following the completion of the sale, the insider now directly owns 540,460 shares of the company’s stock, valued at $6,161,244. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 12.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in MDXG. BlackRock Inc. boosted its stake in shares of MiMedx Group by 136,884.9% in the first quarter. BlackRock Inc. now owns 12,105,354 shares of the medical equipment provider’s stock worth $115,364,000 after buying an additional 12,096,517 shares during the period. Vanguard Group Inc. boosted its position in MiMedx Group by 1.5% in the first quarter. Vanguard Group Inc. now owns 5,094,997 shares of the medical equipment provider’s stock valued at $48,555,000 after buying an additional 73,891 shares during the last quarter. Macquarie Group Ltd. boosted its position in MiMedx Group by 21.1% in the first quarter. Macquarie Group Ltd. now owns 3,544,519 shares of the medical equipment provider’s stock valued at $33,779,000 after buying an additional 618,222 shares during the last quarter. State Street Corp boosted its position in MiMedx Group by 6.7% in the first quarter. State Street Corp now owns 3,249,802 shares of the medical equipment provider’s stock valued at $30,970,000 after buying an additional 203,394 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in MiMedx Group by 53.1% in the first quarter. Wellington Management Group LLP now owns 2,215,575 shares of the medical equipment provider’s stock valued at $21,114,000 after buying an additional 768,857 shares during the last quarter. 50.47% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MDXG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment